Topics:
Gastrointestinal Cancers • Medical Oncology
How do you incorporate trastuzumab, pembrolizumab, and FOLFOX, as per KEYNOTE-811?
Would you give trastuzumab every 2 or 3 weeks, pembrolizumab every 3 or 6 weeks?
Answer from: Medical Oncologist at Academic Institution
I have been thinking about this a lot recently, as the original study was based on treatment with 5FU/cisplatin or capecitabine/oxaliplatin, both of which were q3 week trials. It begs the question as to whether one should consider 5FU/cis over FOLFOX in HER2-positive patients with GEJ adenocarcinoma...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
I agree with incorporating pembrolizumab but my experience with Q6 week pembro has been different from Q3 week with regard to AE's. I would be hesitant to make that leap to Q6 weeks.